Key takeaways
Specialist PE funds outperform generalists below $1 billion in fund size. Above that threshold, the advantage narrows and may reverse depending on the metric.
Operational value creation now drives the majority of PE returns. Deep sector knowledge compounds in this environment in ways that generalist breadth cannot.
The specialist model's biggest risk is its own success. Larger successor funds push GPs past the scale where selectivity holds.
Major allocators are already shifting PE commitments toward smaller, specialist-oriented strategies. CalPERS moved 62% of its PE commitment budget to these funds over 24 months.
The performance data that launched a thousand pitch decks
Specialist private equity funds outperform generalists. That finding shows up in McKinsey's 2026 report, in Cambridge Associates' landmark study, and in Preqin's January 2025 analysis. Three different datasets, three different time periods, same directional conclusion. That consistency has made specialization the centerpiece of virtually every sector-focused fundraising pitch.
What those same datasets also show, and what the pitch decks skip, is that the advantage compresses as fund size grows. Above $1 billion, the evidence starts to contradict itself.
Specialists win because they operate differently, not because they time better
McKinsey's data across 2010-22 vintages puts the specialist edge at 17% pooled IRR vs. 13% for generalists, with lower loss ratios (9% vs. 12%). Cambridge Associates found an even wider spread in earlier vintages: 23.2% gross IRR vs. 17.5%, with specialists outperforming in nine of ten years studied. But the returns alone don't explain much. The mechanism behind them does.
Cambridge found that specialists had 14-25% of invested capital in deals valued below cost, compared to 28-31% for generalists. The outperformance came less from picking winners than from systematically avoiding bad deals. A GP who has spent 15 years in healthcare services recognizes the marginal deal that a generalist deploying across seven sectors might not.
Andrea Auerbach, co-author of the Cambridge study and now Global Head of Private Investments at the firm, attributed the edge to “intimate knowledge of an industry” and the advantages it creates across sourcing, operational improvement, and exit positioning.
A 2024 study in the Journal of Financial Economics supports this from a different angle. Spaenjers and Steiner examined US hotel investments and found specialist PE firms achieved higher net income and capital gains through cost savings, while the generalist's comparative advantage was access to cheaper financing. In a market where debt is no longer cheap, the specialist's operational edge may carry more relative weight.
The current environment makes this advantage more pronounced
Operational value creation has moved from thesis to market reality. Hugh MacArthur, chairman of Bain's Global PE practice, framed the 2026 environment as one where “cheap debt and easy multiple expansion are gone for the foreseeable future.”
Bain estimates that deals now need roughly 12% annual EBITDA growth to generate competitive returns, up from a historical baseline closer to 5%. Revenue growth has become the dominant return driver, accounting for approximately 54% of total PE value creation on average.
When returns depend on actually improving businesses rather than riding market tailwinds, deep sector knowledge should, in principle, become harder to replicate. A GP who knows exactly which procurement levers move margin in industrial services, or which pricing structures accelerate retention in healthcare IT, holds an edge that is difficult to build through a generalist portfolio support team, though generalists at scale offset this through other advantages.
The fundraising market reflects this:
The number of new PE firms has declined roughly 18% per annum since 2020.
Buyout fund closings fell 23% in 2025, the fourth consecutive annual decline.
LPs are gravitating toward what Bain describes as “repeatable strategies, sector specialization and consistent distributions.”
McKinsey's framing is blunter: those who are not big “had better be specialized.”
Buy-and-build rewards the GP who knows the sector's fragmentation map
Add-on acquisitions now account for roughly 73% of all buyout activity in the US. That makes buy-and-build the primary PE value creation strategy, and it's one where the specialist advantage shows up in a specific, measurable way.
INSEAD research on buy-and-build outcomes found that successful integration depends on ”in-depth industry knowledge” and sector fluency. Knowing which targets in a fragmented sector are integration-ready, and which carry hidden operational drag, is the difference between a roll-up that compounds value and one that compounds complexity.
PE-backed companies with five or more acquisitions grew revenue at a 19.8% five-year CAGR, compared to 7.4% for companies with no acquisitions. When three-quarters of all PE deals are add-ons, the GP's ability to repeatedly identify, diligence, and integrate targets within a single sector becomes a measurable return driver, not an abstract sourcing claim.
Success is the specialist model's biggest threat
A sector specialist with a $400 million fund can afford to be selective. There are enough attractive deals in the target sector to deploy that capital without compromising on quality. Raise $2 billion in the same sector, and the math changes.
The most common explanations point to deployment pressure: a finite deal universe forces the GP to either accept marginal assets at higher prices, invest outside the stated mandate, or both. The data is consistent with this, but the precise mechanism is difficult to isolate.
The data supports this as specialist outperformance held at every fund size bracket, including above $1 billion, but the spread tightened as the benefits were “somewhat offset in a more competitive market segment.” 70% of specialists in their sample were under $750 million. That concentration is consistent with the idea that the strategy works best at a scale where the addressable universe supports genuine selectivity.
Preqin's more recent data (2012-23 vintages) goes further. Above $1 billion, generalists actually outperform:
$1B to $2.5B: generalists led specialists by 10.4 percentage points on DPI, though the IRR difference was only 0.3 points.
Above $2.5B: generalists led by 10.1 points on DPI and 1.2 on IRR.
Below $1B: specialists maintained a clear DPI advantage.
There are credible structural reasons why generalists may outperform at this scale. Larger funds access proprietary deal flow that smaller specialists cannot reach. They deploy platform-level resources, dedicated operating teams, procurement leverage across a diversified portfolio, management consulting capabilities, that compound across sectors rather than within one.
They negotiate from stronger positions with lenders, advisors, and co-investors. And diversification itself reduces concentration risk, which matters to allocators managing total portfolio volatility. The Spaenjers and Steiner study found that the generalist's strongest comparative advantage was access to cheaper acquisition financing. At scale, that financing edge, combined with platform infrastructure, may outweigh the specialist's operational precision.
The DPI metric measures cash actually returned to investors, and 2.5 times as many LPs now rank it as their most critical performance metric compared to three years ago. On the measure allocators care most about, the specialist advantage disappears at scale. Preqin's own framing on the analysis: “the data is mixed.”
Attentive allocators are already acting on this
While the broader LP market continues consolidating commitments among large platforms (roughly 70% of commitments in 2024-25 went to existing GP relationships), several major allocators are moving capital in the other direction, toward smaller, sector-focused funds where specialist outperformance is most documented.
CalPERS increased the share of its PE commitment budget directed to specialist-oriented strategies from 28% to 62% over a recent 24-month period. The New York State Teachers' Retirement System was reportedly considering raising its small and medium buyout fund target from 45% to 55%. CDPQ and Schroders Capital have made similar shifts.
These are fiduciary allocators with deep analytical resources. Their reallocation toward the segment where the data is strongest, and away from the mega-fund concentration trend, is a signal worth reading alongside the structural changes reshaping LP rosters more broadly.
What platform consolidation means for standalone specialists
As large managers acquire specialist teams through M&A, the standalone specialist's pitch has to accomplish something different than it did five years ago. A platform can now buy a sector-focused GP and fold the capability into a multi-strategy offering, giving allocators the specialist expertise without the concentration risk of a single-sector fund.
The track record alone no longer differentiates when a platform can offer a comparable one inside a broader relationship. What the platform cannot easily replicate is the depth of explanation behind the returns: which mechanisms drove them, how repeatable those mechanisms are, and whether they hold at the fund size currently being raised.
Bottom line
Every successful specialist fund raise creates pressure to raise a bigger one. Management fee economics reward it. LP demand after strong performance encourages it. But the data says the strategy works best below approximately $1 billion, and the advantage fades, or reverses, above that line depending on which metric and time period you examine.
The most prudent decision a specialist GP can make may be to size the next fund below the point where the data suggests selectivity begins to erode. That means, in practice, turning away capital. The GPs willing to do that are better positioned to preserve the conditions that produced the track record.
For allocators, the signal worth watching is whether the GP is willing to constrain growth to protect the conditions that produced the returns being underwritten. The performance tables are backward-looking. The fund sizing decision reveals whether the GP intends to honor the strategy that built them.
Collateral Partners works with GPs to translate operational edge into investor materials that survive IC-level scrutiny.
